Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones

NCT03630926 is registered in ClinicalTrials.gov with Intermountain Health Care, Inc. as lead sponsor.

NCT NCT03630926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03630926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones
Lead sponsor
Intermountain Health Care, Inc.
Phase
Observational
Overall status
Unknown status
Start date
October 16, 2018
Completion date
December 31, 2019
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hypertrophy, bladder stones, kidney stones, prostate cancer